| Caption | The triple combination of STB-C017, aPD-1 and aCTLA-4 prolongs overall survival |
| Source | Syntekabio, Inc. |
| Download | |
| Related Press Releases Links |
Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting |